Abstract: Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human FGF-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human FGF-1 with a tryptophan (based on the 140 amino acid numbering scheme of human FGF-1) are provided. Other amino acid mutations or substitutions may be combined. Polynucleotide sequences encoding the mutant FGF proteins and host cells containing such polynucleotide sequences are provided. Methods of administering a mutant FGF protein to an individual to treat an ischemic condition or disease or a wound or tissue injury are also provided.

Abstract: Surface-binding peptides have the capability of binding to surfaces of biocompatible materials and can thereby be used to immobilize various heterologous molecules of interest onto the surface. This means that surfaces of, for instance, implants and implantable medical devices can be tailored to present various characteristics by immobilizing selected heterologous molecules of interest on the surfaces of the implants and implantable medical devices. The surface-binding peptides consist of 5-17 consecutive amino acids of an extended beta-hairpin motif EIIATMKKKGEKRCLNP (SEQ ID NO: 57) in Interferon gamma-induced protein 10 (IP-10).

Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

Abstract: The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.

Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.

Abstract: Described herein are methods for purifying recombinant, cell culture derived alpha1-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha1-protease inhibitor.

Abstract: Gastrokine-1 (Gkn-1) is a stomach protein that protects the gastrointestinal (GI) tract and has properties to manipulate smooth muscle contraction, prevent NSAID-induced ulceration of the gastrointestinal tract of a mammal, inhibit growth and survival of cancer cells and induce weight loss in a mammal. Previously this protein was designated AMP-18.

Abstract: Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.

Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification.

Abstract: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.

Abstract: The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (PDCs) comprising the mimic peptides disclosed herein. The targets of these mimic peptides include epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). The present disclosure comprises application of the knob-socket computational model to design antibody mimics for proteins.

Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.

Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for carbonic anhydrase IX (CAIX), and provides a CAIX binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10X11LPN?LX16X17X18QX20?X21AFIX25X26LWD. The present disclosure also relates to the use of such a CAIX binding polypeptide as a diagnostic, prognostic agent and/or therapeutic agent.

Abstract: Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG 1 that comprises a kappa light chain constant domain.

Abstract: A method of treating a cocaine-related disorder in an individual is provided, the method including administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In a specific embodiment, the antibody is a monoclonal antibody comprising a murine lambda light chain variable region, a human gamma heavy chain variable region, and a human kappa or lambda light chain constant region.

Abstract: An isolated anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof includes a heavy chain variable domain that includes three CDRs having at least 90% sequence identity to the three heavy chain CDRs of SEQ ID NO: 7, and a light chain variable domain that includes three CDRs having at least 90% sequence identity to the three light chain CDRs of SEQ ID NO: 8.

Abstract: Poly alpha-1,3-glucan ether compounds are disclosed herein comprising positively charged organic groups. The degree of substitution of the ether compounds is about 0.05 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ether compounds having positively charged organic groups, as well as methods of using these ether compounds for increasing the viscosity of a aqueous compositions. Hydrocolloids and aqueous solutions comprising the ether compounds are also disclosed.

Abstract: A composition for encapsulation and an encapsulated apparatus, the composition including a (meth)acrylic alkoxysilane monomer including a moiety represented by Formula 1 or 2, below, or an oligomer thereof; a multifunctional (meth)acrylate monomer or an oligomer thereof; and an initiator, wherein * and ** represent a binding site between elements.

Abstract: Various embodiments provide dye-doped polystyrene microspheres generated using dispersion polymerization. Polystyrene microspheres may be doped with fluorescent dyes, such as xanthene derivatives including kiton red 620 (KR620), using dispersion polymerization. Certain functionalities, such as sodium styrene sulfonate, may be used to shift the equilibrium distribution of dye molecules to favor incorporation of the dye into the particles. Polyelectrolyte materials, such as poly(diallyldimethyl ammonium chloride), PolyDADMAC, may be used to electrostatically trap and bind dye molecules within the particles. A buffer may be used to stabilize the pH change of the solution during dye-doped polystyrene microsphere generation and the buffer may be selected depending on the pKa of the dye being incorporated. The various embodiments may provide dye-doped polystyrene microspheres, such as KR620-doped polystyrene microspheres that are non-toxic and non-carcinogenic.

Abstract: The present invention relates to a novel method for solvent-free preparation of a polymer of (meth)acrylic acid in solution, said polymer having a molecular weigh of less than 8,000 g/mol and a polydispersity index (PI) of 2 to 5 by radical polymerization.

Abstract: A copolymer is prepared by the polymerization of monomers that include an ultraviolet absorbing monomer, and a base-solubility-enhancing monomer. The copolymer is useful for forming a topcoat layer for electron beam and extreme ultraviolet lithographies. Also described are a layered article including the topcoat layer, and an associated method of forming an electronic device.

Abstract: An imprinting method for forming a pattern of a cured product by irradiating a curable composition for imprinting disposed on a substrate with light while the curable composition is in contact with a mold having surface asperities and removing the mold from a cured product of the curable composition. The method includes bringing the mold into contact with the curable composition in a condensable gas atmosphere, wherein the curable composition for imprinting has a viscosity in the range of 1 cP to 40 cP in air at 23° C., and the condensable gas is introduced between the mold and the curable composition such that the curable composition for imprinting has a condensable gas solubility (gas/(curable composition+gas)) (g/g) in the range of 0.1 to 0.4.

Abstract: Biodegradable graft copolymers derived from a carbohydrate, including nitrogen-containing carbohydrates and modified carbohydrates, and at least one ?,?-unsaturated carboxylic acid derivative having superabsorbent properties are disclosed in addition to the substantially adiabatic polymerization process by which the graft copolymers are made. The methods disclosed can be carried out in a variety of currently available stirred and/or continuous commercial reactors. Polymerizations carried out with starch have surprisingly produced substantially quantitative yields of graft copolymer free of residual monomer produced as a moist copolymer. Product work-up typically involves an optional neutralization and drying.

Abstract: The present invention relates to a process for preparing grafted polyalkyl(meth)acrylates (PAMAs) containing dispersant repeating units in the polymer backbone as well as in the grafted layer, which polymers are characterized by a low sulfur content, the products available by this process and their use as an additive to fuels, especially to middle distillates and blends thereof. The present invention further relates to a composition comprising the grafted polyalkyl(meth)acrylates prepared by the process according to the present invention and the use of said composition as an additive component to fuels, especially to middle distillates and blends thereof, and for improving the cold flow properties of fuel oil and fuel oil compositions, especially to middle distillate fuels and blends thereof.

Abstract: The invention relates to a copolymer that can be used as wetting agent and dispersant and contains i) 40-73 mole percent of a base structural unit (A) and ii) 27-60 mole percent of a substituted dicarboxylic acid derivative structural unit (B), the structural unit (B) containing species having a bisamide structure and species having quaternized amino groups.

Abstract: The present invention relates to novolac vinyl esters useful as thermal resistance conferring components for anaerobic curable compositions, and anaerobic curable compositions having such novolac vinyl esters. The compositions are particularly useful as adhesives and sealants.

Abstract: This application describes methods of forming an object. The methods described include flowing a polyhemiaminal (PHA), polyhexhydrotriazine (PHT), or polyoctatriazacane (POTA) precursor mixture to a nozzle of a 3D printer, heating the PHA, PHT, or POTA precursor to a temperature of at least 50° C., dispensing the PHA, PHT, or POTA precursor in a pattern; and, hardening the PHA, PHT, or POTA precursor into a polymer. The PHA and PHT polymers are formed by reacting a primary diamine with a formaldehyde-type reagent. The POTA polymer is formed by reacting a primary diamine with a formaldehyde-type reagent and formic acid. The objects formed using the methods described herein may be made of a single polymer, a single polymer type using multiple diamine monomers, or a mixture of PHA, PHT, and/or POTA polymers with different desired physical properties.

Abstract: A polyurea or polyurea-urethane elastomer comprises a soft polymer segment and a hard polymer segment, wherein the hard polymer segment includes polyurea groups in combination with H-bond accepting chain extenders (HACEs) to reduce the flow temperature (Tflow) while maintaining the excellent mechanical properties such that the resulting polyurea elatomer is rendered melt-processable.

Abstract: The present invention relates to a process for producing a polyurethane, comprising at least the following steps (A) bringing at least one polymer polyol into contact with an amount of from 0.1 to 20 mol %, based on the entire amount of polyisocyanate, of at least one first polyisocyanate, in order to obtain a prepolymer which in essence has terminal hydroxy groups, and (B) bringing the prepolymer from step (A) into contact with at least one second polyisocyanate and optionally with further additives, in order to obtain the polyurethane, to a polyurethane obtainable via said process, and also to the use of this polyurethane as cladding in automobiles, coatings, cables, plug connectors, solar modules, foils, moldings, shoe soles and shoe components, balls and ball components, rollers, fibers, profiles, laminates and wiper blades, hoses, cable plugs, bellows, drag cables, cable sheathing, gaskets, nonwoven fabrics, drive belts, or damping elements.

Abstract: The present invention relates to a pyridinium-based compound of chemical formula 1, an epoxy resin composition comprising the same, and an apparatus manufactured by using the same.

Abstract: A resin composition for transparent substrates comprises an epoxy resin (A) and a curing agent (B), wherein the curing agent (B) comprises a cyclohexane tricarboxylic anhydride.

Abstract: The invention relates to a method for manufacturing polylactide, comprising the steps of mixing lactide and a metal-coordination compound as polymerization catalyst to obtain a reaction mixture, polymerizing the lactide in liquid phase at a temperature of at least 150° C. to form polylactide in liquid phase and allowing the polylactide to solidify, characterized in that the polymerization catalyst comprises a metal-ligand coordination compound whereby the parent ligand answers the formula (I), whereby R represents an H atom, an aliphatic group, a halide atom or a nitro group and the metal is at least one of Zr and Hf. The invented catalysts show kinetics which is comparable to the kinetics of the known Sn-octoate catalyst.

Abstract: In some embodiments, a method of making a polycarbonate composition comprises: polymerizing by an interfacial polymerization, reactants comprising a starting material comprising a bisphenol-A to form a bisphenol-A polycarbonate, wherein the bisphenol-A has a purity of greater than or equal to 99.65 wt % and a sulfur content of less than or equal to 2 ppm. The polycarbonate composition has a free hydroxyl content of less than or equal to 150 ppm, and wherein a molded article of the polycarbonate composition has transmission level greater than or equal to 90.0% at 2.5 mm thickness as measured by ASTM D1003-00 and a yellow index (YI) less than or equal to 1.5 as measured by ASTM D1925.

Abstract: The present invention relates to a method for preparing polyether carbonate polyols by the addition of alkylene oxides and carbon dioxide onto H-functional starter compounds. The method is characterized in that at least one urethane alcohol according to formula (II) is used as an H-functional starter compound, wherein R 1 represents a linear or branched C2 to C24-alkylene which can be optionally interrupted by heteroatoms such as O, S or N and can be substituted; R2 represents a linear or branched C2 to C24-alkylene which can be optionally interrupted by heteroatoms such as O, S or N and can be substituted; R3 represents H, linear or branched C1 to C24-alkyl, C3 to C24-cycloalkyl, C4 to C24-aryl, C5 to C24-arylalkyl, C2 to C24-alkenyl, C2 to 24-alkinyl, that can each be optionally interrupted by heteroatoms such as O, S, or N and/or may each be substituted with alkyl, aryl, and/or hydroxyl.

Abstract: The present invention provides a method for producing low viscosity polyether carbonate polyols having side chains. A double metal cyanide catalyst and a suspension medium, with or without an H-functional starter compound, are initially introduced as a reaction mixture, and alkylene oxides are metered into the reaction mixture in two steps. The difference between the molecular weights of the lightest and the heaviest of the alkylene oxides metered in the two steps is greater than or equal to 24 g/mol, and the lightest alkylene oxide is a C2-C4 alkylene oxide. The alkylene oxides metered in the two steps can be the same or different. The invention also relates to the low viscosity polyether carbonate polyols produced by the method and to the use thereof.

Abstract: The present invention relates to a method for producing higher functional polyether carbonate polyols, said method preferably comprising the steps of ([alpha]) providing a DMC catalyst and; ([alpha][alpha]) a suspending agent that does contain any H-functional groups and/or ([alpha][beta]) an H-functional starter compound ([beta]) adding carbon dioxide and at least one alkylene oxide ([gamma]) adding carbon dioxide and at least two alkylene oxides, wherein these alkylene oxides can be the same as or different from the alkylene oxide or alkylene oxides added in step ([beta]), and ([delta]) adding carbon dioxide and at least one alkylene oxide, wherein this alkylene oxide or these alkylene oxides can be the same as or different from the alkylene oxides added in steps ([beta]) and ([gamma]), at least one of the alkylene oxides in step ([gamma]) having an epoxy functionality of >=2 and, in addition, in the case that no H-functional starter compound is provided in ([alpha]), step ([delta]) includes the addition

Abstract: The invention relates to a device for synthesis of a polymer under separation of a gaseous substance. Said device comprises a reaction chamber (1), which has a top section (11), a middle section (12) and a bottom section (13), an inlet opening (2) which is arranged in the middle section (12), a first outlet opening (3) which is arranged in the bottom section (13), a second outlet opening (4) which is arranged in the top section (11), a first return opening (51), which is arranged in the bottom section (13), a second outlet opening (52), which is arranged under the top section (11), a distribution device (6), which is arranged between the top section (11) and the middle section (12), and a removal device (7) which is arranged to be movable along the top section (11). The invention further relates to a method for synthesis of a polymer which can be carried out in said device.

Abstract: Polyurethane compositions are disclosed herein, as well as methods of making and using such polyesters. In some embodiments, the polyurethanes are formed from monomers derived from natural oils. In some embodiments, the polyurethanes are formed without the use of monomers bearing isocyanate groups.

Abstract: There is described a polysiloxane having the structure: wherein R1, R2, and R3 are independently a hydrocarbon radical, an unsaturated radical, an alkoxy radical, an aryl radical or an alkenyloxy radical, R4 is independently a direct bond or hydrocarbon radical optionally substituted with oxygen and nitrogen, R5 is independently a hydrogen, a halogen, an aliphatic group having from 1 to 6 carbon atoms, an aromatic group having 6 to 8 carbon atoms, an alkoxy group having from 1 to 6 carbon atoms, or an aryloxy group, R6 is independently a hydroxyl group, an amine group, an acid chloride group, or a sulfonyl halide group, x is from 1 to 300; y is from 0 to 50; and z is from 0 to 50. The polysiloxane is used to make various copolymers and polymer blends. A variety of articles can be made using the polysiloxane described as a polymer blend or copolymer.

Abstract: Curable silsesquioxane polymers are described comprising a core comprising a first silsesquioxane polymer and an outer layer comprising a second silsesquioxane polymer bonded to the core. The silsesquioxane polymer of the core, outer layer, or combination thereof comprises reactive groups that are not ethylenically unsaturated groups. The first silsesquioxane polymer of the core is bonded to the second silsesquioxane polymer of the outer layer via silicon atoms bonded to three oxygen atoms. In some embodiments, the outer layer has a higher concentration of reactive groups than the core. In this embodiment, the core may be substantially free of reactive groups. In other embodiments, the core has a higher concentration of reactive groups than the core. In this embodiment, the outer layer may be substantially free of reactive groups. The core and outer layer each comprise a three-dimensional branched network of a different silsesquioxane polymer.

Abstract: A copolymer composition is provided that is formed as the reaction product of (I) a cured polyorganosiloxane intermediate having repeating Si—O—Si units and at least one Si—OH functional group and (II) a polyfluoropolyether silane. The cured polyorganosiloxane intermediate has a surface having a water contact angle ranging from 40° to 90° as measured by ASTM 5946-04. In certain embodiments, the copolymer composition provides improved dust resistance as compared with cured polyorganosiloxanes from which the copolymer composition is formed.

Abstract: A composition and a method are provided for graphene reinforced polyethylene terephthalate (PET). Graphene nanoplatelets (GNPs) comprising multi-layer graphene are used to reinforce PET, thereby improving the properties of PET for various new applications. Master-batches comprising polyethylene terephthalate with dispersed graphene nanoplatelets are obtained by way of compounding. The master-batches are used to form PET-GNP nanocomposites at weight fractions ranging between 0.5% and 15%. In some embodiments, PET and GNPs are melt compounded by way of twin-screw extrusion. In some embodiments, ultrasound is coupled with a twin-screw extruder so as to assist with melt compounding. In some embodiments, the PET-GNP nanocomposites are prepared by way of high-speed injection molding. The PET-GNP nanocomposites are compared by way of their mechanical, thermal, and rheological properties so as to contrast different compounding processes.